Lysine Biotech Logo

LYSINE BIOTECH PRIVATE LIMITED
 Manufacture of drugs, biomarkers and vaccines from Protein and DNA
 

Research and Development

Metabolomics physiology, process development and food chemistry are major thrust areas we focus on for product development in drugs, biomarkers, vaccines and other food ingredients/additives business and all other pharmaceuticals such as tablets, injectable, syrups, powders, ointments aerosols, capsules and liquids for human consumption, secondary metabolites and industrial enzymes. High throughput instrumentation for research activities in our innovation centre is provided by AIC-CCMB, Medical Biotechnology Complex, CCMB Annex-2, IDA Uppal, Genpact Road, Hyderabad, Telangana and Periyar-TBI, PMIST Thanjavur.

Tumor suppressor p53 for cancer therapy in pipeline.

Tumor suppressor p53 interacts (via DNA-binding domain) of amino acids residues position from aa102D to aa292G. In addition to that Tumor suppressor p53 DNA binding domain mutations of two amino acids residues positions of aa248R and aa249R by substitution of other two amino acids residues without mutation position of aa248 and aa249 in different tumor suppressor p53 wild type isoform 1-9. Based on the results, several cancer developments are expected in the future: Tumor suppressor p53 cancer therapy to eradicating 60% of different cancers in human.

Current State-Of-The-Art Problem:
Available.
Severe acute respiratory syndrome coronavirus (SARS-CoV-2) and Severe acute respiratory syndrome coronavirus (SARS-CoV-3 and SARS-CoV-4).

We put emphasize that with this computationally developed, predicts protein sequence while the invention of new novel study suggest that thymine content (uracil) in protein coding ssRNA sequences are randomly distributed. Thymine content distribution is used here to examine SARS (COV-2-4). Frames are arriving as expected, positive single-stranded RNA (+ssRNA) first three frames, in the SARS coronavirus virus genome. Frame 1 prefer to have definite amount of thymine content (SARS-CoV-2). Frame 2 were observed that the thymine content (SARS-CoV-3) and frame 3 were also involved thymine content (SARS-CoV-4). Frame 1, frame 2 and frame 3 prefers to have least amount of adenine content (SARS-CoV-2-4). However, frame 1, frame 2 and frame 3 shows a variable degree of guanine and cytosine content. In addition, the results reveal that there were difference between (SARS-CoV-2-4) and existence. Severe acute respiratory syndrome coronavirus (SARS-CoV-2-4), determined the role of thymine protein coding frames of ssRNA sequences (P. Anandagopu and E.ajasekaran et al.,.2008. Bioinformation. 2, 304-307). In this results Severe acute respiratory syndrome coronavirus (SARS-CoV-2-4) protein coding ssRNA of RdRp, Spike and Nucleocapsid play an important role in such a way to establish host-pathogen interaction.

Severe acute respiratory syndrome-coronavirus (SARS-CoV-1): 2003 : 29751 bp RNA
Severe acute respiratory syndrome coronavirus (SARS-CoV-2) 1st Covid wave 2019: 29903 bp ss-RNA
Severe acute respiratory syndrome coronavirus (SARS-CoV-3) 2nd Covid wave 2021: 29345 bp RNA
Severe acute respiratory syndrome coronavirus (SARS-CoV-4) 3rd Covid wave 2022: 29214 bp RNA
Proposed Solution

Our computational studies provide new insight into the unique specific regulation of the SARS-COVID- 19 specific ORF1,2,3 abc protein coding ssRNA of RdRp, Spike and Nucleocapsid sequences in Severe acute respiratory syndrome coronavirus (SARS-CoV-2-4) virus genomes.

Specific Goals

I). Development of RdRp, E, M gene-specific reverse transcription – quantitative polymerase chain reaction (RT-qPCR) four primers with two probe from RdRp gene and two primers with one probe from E gene and M gene-specific RT-qPCR. Set-up of RT-qPCR kit prototype.

RdRp-RNA-dependent RNA polymerase gene
>Frame 1 prefers to have definite amount of protein coding ssRNA of RdRp gene/protein (SARS-CoV-2) 1st Covid wave 2019.
>Frame 2 prefers to have definite amount of protein coding RNA of RdRp gene/protein (SARS-CoV-3) 2nd Covid wave 2021.
>Frame 3 prefers to have definite amount of protein coding RNA of RdRp gene/protein (SARS-CoV-4) 3rd Covid wave 2022.
>Frame 1, frame 2 and frame 3 prefers to have definite amount of protein coding ssRNA of RdRp gene/protein (SARS-CoV-2-4) 4th Covid wave 2022.
E -Envelope small membrane gene
>Frame 1 prefers to have definite amount of protein coding ssRNA of Envelope gene/protein (SARS-CoV-2&3) 1st and 2nd Covid wave (2019-2021).
>Frame 2 prefers to have definite amount of protein coding RNA of Envelope gene/protein (SARS-CoV-4) 3rd Covid wave 2022.
>Frame 3 not prefers to have definite amount of protein coding RNA of Envelope gene in Severe acute respiratory syndrome coronavirus NA.
>Frame 1 and frame 2 prefers to have definite amount of protein coding ssRNA of Envelope gene/protein (SARS-CoV-2-4) 4th Covid wave 2022.
M - Membrane gene
>Frame 1 prefers to have definite amount of protein coding RNA of Membrane gene/protein (SARS-CoV-4) 3rd Covid wave 2022.
>Frame 2 not prefers to have definite amount of protein coding RNA of Membrane gene in Severe acute respiratory syndrome coronavirus NA.
>Frame 3 prefers to have definite amount of protein coding ssRNA of Membrane gene/protein (SARS-CoV-2&3) 1st and 2nd Covid wave (2019-2021).
>Frame 1 and frame 3 prefers to have definite amount of protein coding ssRNA of Envelope gene/protein (SARS-CoV-4, & SARS-CoV-2&3) 4th Covid wave 2022.

II) Development of Spike protein-specific Antigen-/Antibody for enzyme-linked immunosorbent assay (ELISA) analysis. Set-up of ELISA kit prototype.

III) Development of nucleocapsid protein COVID-19 specific IgM and IgG Dual antibody detection kit using recombinant antigens and collodial gold conjugate. Set-up of IgM and IgG Dual antibody and antigen kits prototype.

Spike & nucleocapsid gene/proteins
>Frame 1 prefers to have definite amount of protein coding sequence of Spike & nucleocapsid gene/proteins (SARS-CoV-4) 3rd Covid wave 2022.
>Frame 2 prefers to have definite amount of protein coding sequence of Spike & nucleocapsid gene/proteins (SARS-CoV-2) 1st Covid wave 2019.
>Frame 3 prefers to have definite amount of protein coding sequence of Spike & nucleocapsid gene/proteins (SARS-CoV-3) 2nd Covid wave 2021.
>Frame 1, frame 2 and frame 3 prefers amount of protein coding of Spike & nucleocapsid proteins (SARS-CoV-4,SARS-CoV-2 & SARS-CoV-3)4th Covid wave 2022.

IV) Protein subunit vaccine (SARS-CoV-2(frame 2) Receptor binding domain (RDB)52, SARS-CoV-3(frame 3) (RDB) and SARS-CoV-4(frame 1) (RDB)).

V) Protein subunit vaccine (SARS-COV-2-4 spike, nucleocapsid, RdRp proteins and nasal application).

Current Available:
Human coronavirus OC43 (HCoV-OC43): 2020 : 30741 bp RNA
>Frame 2 prefers to have definite amount of protein coding RNA of RdRp in Human coronavirus OC43 (HCoV-OC43) 2nd Covid wave 2021
>Frame 3 prefers to have definite amount of protein coding of Spike & nucleocapsid proteins Human coronavirus OC43 (HCoV-OC43) 2nd Covid wave 2021
LIST OF ABBREVIATIONS

+ssRNA- positive single-stranded RNA

RNA- Ribonucleic Acid (RNA)

Thymine content- XTX 16 Codons- Where X (A, T, G and C)

Adenine content- XAX 16 Codons- Where X (A, T, G and C)

Guanine content- XGX 16 Codons- Where X (A, T, G and C)

Cytosine content-XCX 16 Codons- Where X (A, T, G and C)

XTX 16 Codons – Large Hydrophobic Residues (LHRs) , F, I, L, M and V

open reading frame (ORF) ssRNA

Frame 1- open reading frame (ORF1)

Frame 2- open reading frame (ORF2)

Frame 3- open reading frame (ORF3)

Publications

I).Renganathan Senthil*, Manokaran Sakthivel, Singaravelu Usha, 2021. Structure-based drug design of peroxisome proliferator-activated receptor gamma inhibitors: ferulic acid and derivatives. J Biomol Struct Dyn. 39(4):1295-1311. doi: 10.1080/07391102.2020.1740790.

II).Konda Mani Saravanan, Haiping Zhang, Renganathan Senthil*, Kevin Kumar Vijayakumar, Vignesh Sounderrajan, Yanjie Wei, Harshavardhan Shakila, 2020. Structural basis for the inhibition of SARS-CoV2 main protease by Indian medicinal plant-derived antiviral compounds. J Biomol Struct Dyn. 1-9. doi: 10.1080/07391102.2020.1834457.

III).Mahendrarajan Venkatramanan, Pitchaipillai Sankar Ganesh, Renganathan Senthil*, Jeyachandran Akshay, Arumugam Veera Ravi, Kulanthaivel Langeswaran, Jamuna Vadivelu, Samuthira Nagarajan, Kaliaperumal Rajendran, Esaki Muthu Shankar, 2020. Inhibition of Quorum Sensing and Biofilm Formation in Chromobacterium violaceum by Fruit Extracts of Passiflora edulis. ACS Omega.5(40):25605-25616. doi: 10.1021/acsomega.0c02483.

IV).Subrata Pramanik, Manisha Thaker, Ananda Gopu Perumal*, Rajasekaran Ekambaram, Naresh Poondla, Markus Schmidt, Pok‐Son Kim, Arne Kutzner, Klaus Heese, 2020. Proteomic Atomics Reveals a Distinctive Uracil‐5‐Methyltransferase. Molecular Informatics. Vol. 39, Issue 5, DOI:10.1002/minf.201900135.

V).G.dayana jeyaleela, J. Rosaline vimala, R. Senthil, P. Anandagopu* and K. Manjula, 2019. Isolation, Characterization, Molecular Docking and in vitro Studies of Inhibitory Effect on the Growth of Struvite Crystal Derived from Melia dubia Leaf Extract. Asian Journal of Chemistry. Vol. 31, No. 11, 2628-26345).

VI).V. Dhivya Jensi, Perumal Ananda Gopu*, 2018. Evaluation of Hypolipidemic Activity of Various Phytoconstituents from Terminalia arjuna (Roxb.ex DC.) in Rat Fed with High Fat Diet. Int. J. Pharm. Sci. Rev. Res., 50 (2),8: 41 -48.

VII).V.Dhivya Jensi, P. Ananda Gopu*, 2018.Comparative Analysis of Quercetin and Leucocynidin against HMG-CoA reductase and their evaluation of hypolipidemic activity. Journal of Pharmaceutical Sciences and Research. Vol.10, Issue 12, 3417-3421.

Lysine Biotech